New alliance will target major risk factor for Alzheimer's

Share this article:

A new collaboration will see four leading academic research laboratories working with AstraZeneca to study a major risk factor for Alzheimer's disease. Steven Paul, M.D., of Weill Cornell Medical College and AstraZeneca jointly announced the A5 Alliance. Collectively, the alliance will examine the apolipoprotein E4 genotype (ApoE). “We are convinced that ApoE represents a major piece of the Alzheimer's disease puzzle,” Paul noted. Additional members include David Holtzman, M.D. of Washington University in St. Louis, Peter Davies, Ph.D., of The Feinstein Institute for Medical Research and Cheryl Wellington, Ph.D., of the University of British Columbia.

Share this article:
close

Next Article in Products

More in Products

Malnutrition remains issue

Identifying malnutrition in patients upon admission to a hospital is a low-cost way to improve patient outcomes and reduce readmissions, a new report says. Alleviating Hospital-Based Malnutrition: A Baseline Progress Report is an assessment of hospital-based malnutrition released in connection with the first anniversary of ...

Construction Specialties introduces wall and door protection

Construction Specialties introduces wall and door protection

Construction Specialties Inc. (C/S) has debuted a new line of wall and door protection, Acrovyn by Design and Acrovyn Doors by Design. The products embed high-resolution images and logos as ...

BioSensics launches ActivePERS fall detection

BioSensics launches ActivePERS fall detection

BioSensics has introduced ActivePERS, a personal emergency response and telemonitoring solution for seniors.